secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0001178670-25-000031
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam co-founder Dr. Phillip A. Sharp to retire from board effective May 8, 2025
--------------------------------------------------------------------------------

- Dr. Sharp informed the board on March 3, 2025; retirement is not due to any disagreement.
- He will continue to serve on Alnylam's Scientific Advisory Board after retirement.
- Dr. Sharp co-founded Alnylam in 2002 and is a Nobel Prize winner for RNA splicing.
- The company issued a press release on March 5, 2025 announcing the transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000117867025000031/0001178670-25-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000117867025000031/alny-20250303.htm
  HTML page:      https://secwatch.observer/filing/0001178670-25-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer